Search - tctmd.com

Displaying 61 - 80 of 406

Sort: Relevancy | Date

TCTMD’s Top 10 Most Popular Stories for June 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for June 2022

July 04, 2022

Rivaroxaban Offers VTE Protection in Postprocedure PAD Patients

News Daily News

Rivaroxaban Offers VTE Protection in Postprocedure PAD Patients

June 29, 2022

‘Less Is More’ for Patients With AF and Stable CAD: AFIRE Analysis

News

‘Less Is More’ for Patients With AF and Stable CAD: AFIRE Analysis

June 17, 2022

Subclinical Thrombosis After TAVI Benign, at Least to 3 Years

News Daily News

Subclinical Thrombosis After TAVI Benign, at Least to 3 Years

Michael O'Riordan

June 07, 2022

Thrombotic vs Bleeding Risks Post-TAVI: Insights From GALILEO

News Conference News EuroPCR 2022

Thrombotic vs Bleeding Risks Post-TAVI: Insights From GALILEO

Yael L. Maxwell

May 23, 2022

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

News Conference News ACC 2022

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

April 05, 2022

Subclinical Leaflet Thrombosis After TAVI Linked to Higher Mortality

News Daily News

Subclinical Leaflet Thrombosis After TAVI Linked to Higher Mortality

Michael O'Riordan

March 10, 2022

Fewer Diabetic Complications Seen When NOACs Given for AF

News Daily News

Fewer Diabetic Complications Seen When NOACs Given for AF

February 22, 2022

ACTION-CVT: DOACs Look Like a Good Option for Cerebral Venous Thrombosis

News Conference News ISC 2022

ACTION-CVT: DOACs Look Like a Good Option for Cerebral Venous Thrombosis

February 10, 2022

TCTMD’s Top 10 Most Popular Stories for January 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2022

January 31, 2022

DOACs Should Be Standard to Prevent VTE Recurrence in Cancer: Meta-analysis

News Daily News

DOACs Should Be Standard to Prevent VTE Recurrence in Cancer: Meta-analysis

January 20, 2022

Shorter Anticoagulation an Option for Young Patients With Provoked VTE

News Daily News

Shorter Anticoagulation an Option for Young Patients With Provoked VTE

January 11, 2022

MICHELLE Published: Low-Dose Rivaroxaban Cuts VTE Risk After COVID-19 Admission

News Daily News

MICHELLE Published: Low-Dose Rivaroxaban Cuts VTE Risk After COVID-19 Admission

December 29, 2021

Apixaban Appears Safer, More Effective Than Rivaroxaban in Medicare Study

News Daily News

Apixaban Appears Safer, More Effective Than Rivaroxaban in Medicare Study

December 27, 2021

FDA Approves Two Additional Indications for Rivaroxaban in Children

News Daily News

FDA Approves Two Additional Indications for Rivaroxaban in Children

December 21, 2021

Select COVID-19 Patients May Benefit From Postdischarge Anticoagulation

News Daily News

Select COVID-19 Patients May Benefit From Postdischarge Anticoagulation

November 25, 2021

TCTMD’s Top 10 Most Popular Stories for October 2021

News Daily News

TCTMD’s Top 10 Most Popular Stories for October 2021

November 02, 2021

Half-Dose DOAC May Be a Good Post-Watchman Option

News Daily News

Half-Dose DOAC May Be a Good Post-Watchman Option

October 14, 2021

Rivaroxaban Again Linked to More Bleeding vs Other DOACs

News Daily News

Rivaroxaban Again Linked to More Bleeding vs Other DOACs

October 11, 2021

Rivaroxaban Safe, Effective in Renal Disease: VOYAGER PAD

News Daily News

Rivaroxaban Safe, Effective in Renal Disease: VOYAGER PAD

August 10, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.